0000950170-24-026885.txt : 20240306
0000950170-24-026885.hdr.sgml : 20240306
20240306091559
ACCESSION NUMBER: 0000950170-24-026885
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240206
FILED AS OF DATE: 20240306
DATE AS OF CHANGE: 20240306
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Apeiron Presight Capital Fund II, L.P.
CENTRAL INDEX KEY: 0001840676
ORGANIZATION NAME:
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41944
FILM NUMBER: 24724525
BUSINESS ADDRESS:
STREET 1: 340 S LEMON AVE #3391
CITY: WALNUT
STATE: CA
ZIP: 91789
BUSINESS PHONE: 4156382393
MAIL ADDRESS:
STREET 1: 340 S LEMON AVE #3391
CITY: WALNUT
STATE: CA
ZIP: 91789
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Apeiron Investment Group Ltd.
CENTRAL INDEX KEY: 0001845711
ORGANIZATION NAME:
STATE OF INCORPORATION: O1
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41944
FILM NUMBER: 24724526
BUSINESS ADDRESS:
STREET 1: BLOCK A, APT.12
STREET 2: IL-PIAZZETTA, TOWER ROAD
CITY: SLIEMA
STATE: O1
ZIP: SLM1605
BUSINESS PHONE: 44 7557 251 563
MAIL ADDRESS:
STREET 1: BLOCK A, APT.12
STREET 2: IL-PIAZZETTA, TOWER ROAD
CITY: SLIEMA
STATE: O1
ZIP: SLM1605
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Angermayer Christian
CENTRAL INDEX KEY: 0001845872
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41944
FILM NUMBER: 24724524
MAIL ADDRESS:
STREET 1: BLOCK A, APT.12
STREET 2: IL-PIAZZETTA, TOWER ROAD
CITY: SLIEMA
STATE: O1
ZIP: SLM1605
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Alto Neuroscience, Inc.
CENTRAL INDEX KEY: 0001999480
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 834210124
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 369 SOUTH SAN ANTONIO RD.
CITY: LOS ALTOS
STATE: CA
ZIP: 94022
BUSINESS PHONE: 773-255-5012
MAIL ADDRESS:
STREET 1: 369 SOUTH SAN ANTONIO RD.
CITY: LOS ALTOS
STATE: CA
ZIP: 94022
4
1
ownership.xml
4
X0508
4
2024-02-06
true
0001999480
Alto Neuroscience, Inc.
ANRO
0001845711
Apeiron Investment Group Ltd.
66 & 67 AMERY STREET
SILEMA
O1
SLM1707
MALTA
false
false
false
true
See Remarks
0001840676
Apeiron Presight Capital Fund II, L.P.
66 & 67 AMERY STREET
SILEMA
O1
SLM 1707
MALTA
false
false
false
true
See Remarks
0001845872
Angermayer Christian
66 & 67 AMERY STREET
SILEMA
O1
SLM 1707
MALTA
false
false
false
true
See Remarks
false
Common Stock
2024-02-06
4
C
false
251881
A
251881
D
Common Stock
2024-02-06
4
C
false
674658
A
674658
I
By Apeiron Presight Capital Fund II, L.P.(
Warrants to Purchase Series A Preferred Stock
2024-02-06
4
C
false
444561
D
Common Stock
69304
0
D
Series A Preferred Stock
2024-02-06
4
C
false
406072
D
Common Stock
182577
0
D
Series A Preferred Stock
2024-02-06
4
C
false
1063918
D
Common Stock
478359
0
I
By Apeiron Presight Capital Fund II, L.P.
Series B Preferred Stock
2024-02-06
4
C
false
416665
D
Common Stock
196299
0
I
By Apeiron Presight Capital Fund II, L.P.
In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis.
The reportable securities are held by Apeiron Investment Group Ltd. ("Apeiron"). Christian Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities.
The reportable securities are held by Apeiron Presight Capital Fund II, L.P. ("Apeiron Presight"). Apeiron Investment Group Ltd. ("Apeiron") and Fabian Hansen are the managing members of Presight Capital Management I, L.L.C. ("Presight Management"), which is the general partner of Apeiron Presight. As a result, each of Apeiron, Mr. Hansen and Presight Management may be deemed to share beneficial ownership of the securities.
In connection with the closing of the Issuer's initial public offering, the Warrants were exercised on a cashless basis into shares of Series A Preferred Stock, which were automatically converted into shares of Common Stock on a 2.2241 for 1 basis.
In connection with the closing of the Issuer's initial public offering, each share of Series B Preferred automatically converted into common stock on a 2.1226069 for 1 basis.
The Form 3 filed by the Reporting Persons on February 2, 2024 inadvertently included securities Apeiron SICAV Ltd. The Reporting Persons do not have voting or dispositve power over such securities and disclaim any beneficial ownership of such securities. As a result of foregoing, the Reporting Persons were inadvertently characterized as 10% owners.
Apeiron Investment Group Ltd. By: /s/ Julien Hoefer, Director
2024-03-05
Apeiron Presight Capital Fund II, L.P. By: /s/ Julien Hoefer, Director
2024-03-05
/s/ Christian Angermayer
2024-03-05